MedTrace Logo

Study of NXN 188 for the Treatment of Migraine With Aura

NCT00920686 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 239

Last updated 2014-08-11

Study results available
· View outcomes & findings →

Summary

NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.

Conditions

  • Migraine With Aura

Interventions

DRUG

NXN-188

NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules

DRUG

placebo

administered as 3 placebo hard gelatin capsules

DRUG

sumatriptan succinate

administered in a hard gelatin capsule with 2 capsules of placebo

Sponsors & Collaborators

  • NeurAxon Inc.

    lead INDUSTRY

Principal Investigators

  • Guy Boudreau, MD · Hopital Notre-Dame Du Chum, Montreal

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00920686 on ClinicalTrials.gov